Pharma: A recent setback in a cholesterol drug trial raises concerns about the viability of competing multibillion-dollar treatments in the market.
With Novartis stumbling, the pressure mounts on Amgen and Eli Lilly to transform reduced Lp(a) levels into a drop in heart attacks and strokes. The competition just got more intense! 💔💪 #HeartHealth #PharmaRace
What's Your Reaction?
Like
0
Dislike
0
Love
0
Funny
0
Angry
0
Sad
0
Wow
0
